Novartis Pharma B.V.
Location
Noord-Holland
Founded
1948-02-10
Website
Risk Signals
21161 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Drugs, Drug Proprietaries, and Druggists' Sundries), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Novartis Pharma B.V.
Live alerts from global media, monitored by Business Radar
2023-07-17 (watson.ch)
Novartis is fighting for the trust of investors: the management duo is in debt
It looked like a good year at Novartis - until the patent dispute over sales champion Entresto startled the shareholders.
Read more
2023-07-17 (watson.ch)
Novartis is fighting for the trust of investors: the management duo is in debt
It looked like a good year at Novartis - until the patent dispute over sales champion Entresto startled the shareholders.
Read more
2022-09-15 (globenewswire.com)
OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2022
OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2022 SIGNIFICANT STRATEGIC AND OPERATIONAL PROGRESS TOWARDS BECOMING A GLOBAL VIRAL...
Read more
2019-11-11 (businesslive.co.za)
Aspen Pharmacare agrees to sell Japanese unit
Aspen has been disposing of assets to bring down debt, and want to sell its Japanese operations to Sandoz, a division of Switzerland-based Novartis
Read more
2019-11-11 (businesslive.co.za)
Aspen Pharmacare agrees to sell Japanese unit
Aspen has been disposing of assets to bring down debt, and want to sell its Japanese operations to Sandoz, a division of Switzerland-based Novartis
Read more
2019-11-11 (businesslive.co.za)
Aspen Pharmacare agrees to sell Japanese unit
Aspen has been disposing of assets to bring down debt, and want to sell its Japanese operations to Sandoz, a division of Switzerland-based Novartis
Read more
2019-05-09 (fiercepharma.com)
Takeda sells Shire’s Xiidra, transfers 400 staffers to Novartis in $3.4B deal
Takeda is looking to lighten the huge debt burden from the Shire buyout. Novartis wants to beef up its eye medicine portfolio after the Alcon spinoff. | Takeda is looking to lighten the huge debt burden from the Shire buyout.
Read more
2018-02-22 (periodista.gr)
The staff and the debt collectors who are doing psychotherapy are screaming against Periodista.gr - In passing, but first...
Yesterday's revelatory report about the family's sordid past caused a sensation
Read more
2017-07-04 (investorschronicle.co.uk)
Oxford BioMedica refinances debt
The group has taken out another very expensive loan
Read more
2015-10-01 (globenewswire.com)
XOMA Announces Development and Commercialization Agreement for First-in-Class Anti-TGF-beta Antibody Program in Immuno-Oncology
BERKELEY, Calif., Oct. 1, 2015 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies,...
Read more
2013-03-31 (business-standard.com)
Torrent Pharma to buy Elder's India business for Rs 2,000 cr
Read more about Torrent Pharma to buy Elder's India business for Rs 2,000 cr on Business Standard. Deal to give debt relief to Mumbai-based seller; analysts expect pressure on Torrent's margins
Read more
2013-03-31 (business-standard.com)
Torrent Pharma to buy Elder's India business for Rs 2,000 cr
Read more about Torrent Pharma to buy Elder's India business for Rs 2,000 cr on Business Standard. Deal to give debt relief to Mumbai-based seller; analysts expect pressure on Torrent's margins
Read more